Sivelestat
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Distress Syndrome, Adult
Conditions
Respiratory Distress Syndrome, Adult, Acute Lung Injury
Trial Timeline
Aug 1, 2001 → Dec 1, 2002
NCT ID
NCT00036062About Sivelestat
Sivelestat is a phase 1/2 stage product being developed by Eli Lilly for Respiratory Distress Syndrome, Adult. The current trial status is completed. This product is registered under clinical trial identifier NCT00036062. Target conditions include Respiratory Distress Syndrome, Adult, Acute Lung Injury.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00036062 | Phase 1/2 | Completed |
Competing Products
20 competing products in Respiratory Distress Syndrome, Adult